Newsletter Instruction Sheet BioPharm International eBulletin

TO: enl.advanstarsupport@mpe.hcl.com

Name of Print Publication: BioPharm International

Name of Newsletter: BioPharm Science and Business Bulletin

#### Subject Line: [Grünenthal, Mesoblast Partner on Innovative Cell Therapy for Chronic Low Back Pain](http://www.biopharminternational.com/gr-nenthal-mesoblast-partner-innovative-cell-therapy-chronic-low-back-pain); [Passage Bio Establishes New Gene Therapy Development Program for Nerve Disorder](http://www.biopharminternational.com/passage-bio-establishes-new-gene-therapy-development-program-nerve-disorder-0)

Billing Code: 6060.5000712.1304.51320205.000000.0000.000000

From Line: Rita Peters, Editorial Director, BioPharm International

Mail Date: September 17, 2019

Time to send: 9 am Eastern US time

Science & Business Bulletin:

Mails from list name: biopharminternational

Mails to these TWO lists:

Mailing #1 Engaged Opt-ins/Prospects

ECN Group BIOP\* - Science & Business Bulletin

ECN Filter Enews Master filter

Mailing #2 Advertisers

ECN Group BIOP\_Advertiser

ECN Filter BIOP Adver

\*Please “clear” the recency limit for these two mailings

Contact Person:

Name: Rita Peters

Email: RPeteres@mmhgroup.com

Phone: 732.346.3038

Name: Susan Haigney

Email: SHaigney@mmhgroup.com

Phone: 732.346.3045

Name: Lauren Lavelle

Email: LLavelle@mmhgroup.com

Phone: 609.250.4652

Names of People who should receive a proof:

Editorial:

Rita Peters

Susan Haigney

Lauren Lavelle

Feliza Mirasol (FMirasol@mmhgroup.com)

Sales/ads:

Mike Tracey [MTracey@mmhgroup.com](mailto:MTracey@mmhgroup.com)

Scott Vail SVail@mmhgroup.com

Kristi Stevenson [KStevenson@mmhgroup.com](mailto:kristi.stevenson@ubm.com)

\*\*[Pick up template from the following email]:

<http://images2.advanstar.com/biopharm/Enewsr/2016/BIOP_eBulletin_02022016.html>

BioPharm International eBulletin

View in browser.

<newsletter header>

Link header to: [http://www.biopharminternational.com?cfcache=true](http://www.biopharminternational.com/?cfcache=true)

Date of newsletter (September 17, 2019)

<Top menu>

BioPharmInternational.com <[http://www.biopharminternational.com?cfcache=true](http://www.biopharminternational.com/?cfcache=true)>

Current Issue <http://www.biopharminternational.com/biopharm-international-09-01-2019>

Subscribe <<http://eforms.kmpsgroup.com/jointforms/Forms/Subscription.aspx?pubcode=BIOP&step=form&source=BIOPEBTN>>

Forward <a href="ECN\_Social\_F2F”>

Twitter icon <https://twitter.com/BioPharmIntl>

LinkedIn icon https://www.linkedin.com/groups/4027200/

<section head>

**Top Stories**

#### Headline with link: [Grünenthal, Mesoblast Partner on Innovative Cell Therapy for Chronic Low Back Pain](http://www.biopharminternational.com/gr-nenthal-mesoblast-partner-innovative-cell-therapy-chronic-low-back-pain)

**Summary with Read More link:** The companies will develop and commercialize a Phase III cell therapy candidate for treating chronic low back pain in a deal worth potentially $1 billion.

**URL:** http://www.biopharminternational.com/gr-nenthal-mesoblast-partner-innovative-cell-therapy-chronic-low-back-pain?topic=361,330,371

**Headline with link:** [Passage Bio Establishes New Gene Therapy Development Program for Nerve Disorder](http://www.biopharminternational.com/passage-bio-establishes-new-gene-therapy-development-program-nerve-disorder-0)

**Summary with Read More link:** Passage Bio has licensed a sixth gene therapy development program under its partnership with the University of Pennsylvania for the clinical development of a potential treatment for a nerve disorder.

**URL:** http://www.biopharminternational.com/passage-bio-establishes-new-gene-therapy-development-program-nerve-disorder-0?topic=371,330,361

<section 1, right>

300x250 ad

<Subscribe>

Subscribe image, description, and link

<http://eforms.kmpsgroup.com/jointforms/Forms/Subscription.aspx?pubcode=BIOP&step=form&source=BIOPEBSUB>

Subscription Offers

<http://eforms.kmpsgroup.com/jointforms/Forms/Subscription.aspx?pubcode=BIOP&step=form&source=BIOPEBSUMIM>

<section head>

**Industry News**

Headline with link: [GSK Announces First Biologic for the Treatment of Eosinophilic Asthma in Pediatric Patients](http://www.biopharminternational.com/node/384554)

**Summary with Read More link:** FDA approved the drug after a successful open-label study of children aged six to 11 years and living with the condition.

**URL:** http://www.biopharminternational.com/node/384554?topic=361,323

Headline with link: [GE Healthcare to Partner with NIBRT for Biopharma Education Program](http://www.biopharminternational.com/ge-healthcare-partner-nibrt-biopharma-education-program-0)

**Summary with Read More link:** The companies plan to create a new curriculum focusing on single-use applications training, cell therapy technology, process efficiency strategies, process development methodologies, and chromatography proficiency.

**URL:** http://www.biopharminternational.com/ge-healthcare-partner-nibrt-biopharma-education-program-0?topic=327,330

More Industry News

<http://www.biopharminternational.com/autolist/38/more>

<section head>

**Biopharma News**

Headline with link: [Collaboration Aims to Drive Commercialization of Next-Generation Therapies](http://www.biopharminternational.com/collaboration-aims-drive-commercialization-next-generation-therapies)

**Summary with Read More link:** TrakCel and McKesson have formed a collaboration that is aimed at accelerating commercialization of cell and gene therapies by leveraging services to enable a more efficient development pathway.

**URL:** http://www.biopharminternational.com/collaboration-aims-drive-commercialization-next-generation-therapies?topic=371,327,330

Headline with link: [IRBM Signs Agreement with MD Anderson Cancer Center for MAb Development](http://www.biopharminternational.com/irbm-signs-agreement-md-anderson-cancer-center-mab-development)

**Summary with Read More link:** The organization will utilize the cancer center’s Research for Biologics and Immunotherapy Translation platform for the development of therapeutic monoclonal antibodies against a novel immune checkpoint target.

**URL:** http://www.biopharminternational.com/irbm-signs-agreement-md-anderson-cancer-center-mab-development?topic=330

More Biopharma News <<http://www.biopharminternational.com/taxonomy/term/1995>>

<section head>

**Supplier News**

Headline with link: [Bayer Licenses GlymaxX Antibody Technology from ProBioGen](http://www.biopharminternational.com/bayer-licenses-glymaxx-antibody-technology-probiogen-0)

**Summary with Read More link:** Bayer will use ProBioGen’s GlymaxX technology to maximize the potency of its antibody drug candidate in development for oncological indications.

**URL:** http://www.biopharminternational.com/bayer-licenses-glymaxx-antibody-technology-probiogen-0?topic=361,371,323

Headline with link: [ABEC Launches 6000-L Single-Use Bioreactor](http://www.biopharminternational.com/abec-launches-6000-l-single-use-bioreactor)

**Summary with Read More link:** The company’s Custom Single Run product line now has available bioreactors with working volumes of up to 6000 L.

**URL:** http://www.biopharminternational.com/abec-launches-6000-l-single-use-bioreactor?topic=384,323,385

More Supplier News <http://www.biopharminternational.com/taxonomy/term/32109>

<section 3, two-col format>

<section head>

**Regulatory News**

Headline with link: [Adverse Event Reporting for Compounded Drugs](http://www.biopharminternational.com/adverse-event-reporting-compounded-drugs-0)

**Summary with Read More link:** FDA issued a statement about the importance of reporting adverse events resulting from the use of compounded drugs.

**URL:** http://www.biopharminternational.com/adverse-event-reporting-compounded-drugs-0?topic=333,337,335,381

Headline with link: [Xeris Pharmaceuticals Gets FDA Nod for Liquid Glucagon](http://www.biopharminternational.com/xeris-pharmaceuticals-gets-fda-nod-liquid-glucagon)

**Summary with Read More link:** Xeris Pharmaceuticals has received FDA approval for GVOKE (glucagon), a liquid glucagon for treating hypoglycemia.

**URL:** http://www.biopharminternational.com/xeris-pharmaceuticals-gets-fda-nod-liquid-glucagon?topic=337,334

More Regulatory News <http://www.biopharminternational.com/regulatory-authority-actions>

**FEATURE TOPICS**

UPSTREAM PROCESSING

<http://www.biopharminternational.com/taxonomy/term/2737>

Headline with link: [Cell-Culture Advances Test Bioreactor Performance Models](http://www.biopharminternational.com/node/384057)

**Summary with Read More link** The evolution of cell-culture technology is driving the need for improvements in modeling solutions.

**URL:** http://www.biopharminternational.com/node/384057?topic=387,316,323,302

QUALITY

<http://www.biopharminternational.com/taxonomy/term/2493>

Headline with link: [Best Practices for Studying Stability in Biologics](http://www.biopharminternational.com/node/383942)

**Summary with Read More link** Industry experts discuss the challenges and regulations of setting up a CGMP-compliant stability testing program.

**URL:** http://www.biopharminternational.com/node/383942?topic=333,335,337

ANALYTICAL METHODS  
<http://www.biopharminternational.com/taxonomy/term/2792>

Headline with link: [Improving Oligonucleotide Analysis](http://www.biopharminternational.com/node/384315)

**Summary with Read More link** Oligonucleotides, which are classified as both small molecules and biomolecules, pose unique analytical challenges. High-resolution mass spectrometry is becoming a method of choice for their development.

**URL:**  http://www.biopharminternational.com/node/384315?topic=383

OUTSOURCING

<http://www.biopharminternational.com/taxonomy/term/2051>

Headline with link: [Biologics Continue to Grow and Create Outsourcing Opportunities](http://www.biopharminternational.com/node/383959)

**Summary with Read More link:** CDMOs are adding facilities and services to their portfolios in anticipation of the biologics industry’s continued growth.

**URL:** http://www.biopharminternational.com/node/383959?topic=381

<section head>

**Events**

**[PDA Data Integrity Workshop](http://www.pharmtech.com/pda-data-integrity-workshop?__hstc=126692114.e0f53ae3eb3135be85d81ed5ba7ae62b.1557928684893.1561562437940.1561747150022.92&__hssc=126692114.8.1561747150022&__hsfp=1517700082)**

URL: http://www.pharmtech.com/pda-data-integrity-workshop

September 18­­–19, 2019

[**American Pharma Outsourcing Summit**](http://www.pharmtech.com/american-pharma-outsourcing-summit-4)

URL: http://www.pharmtech.com/american-pharma-outsourcing-summit-4

September 23­­–24, 2019

[**Wearable Injectors and Connected Devices Conference 2019**](http://www.pharmtech.com/wearable-injectors-and-connected-devices-conference-2019)

URL: http://www.pharmtech.com/wearable-injectors-and-connected-devices-conference-2019

October 9­­–10, 2019

More Events <http://www.biopharminternational.com/events>

<section 7, 2 col format>

<section head>

**eBook**

**Single-Use Systems 2019 eBook**

The editors examine the technology, practices, and regulatory approval questions facing

companies employing single-use technologies for commercial manufacturing.

<http://findpharma.hs-sites.com/single-use-systems-2019>

<insert cover image to the left>

<Footer>

CONTRIBUTE < http://www.biopharminternational.com/biopharm-international-info-authors>

CONTACT EDITORS < http://www.biopharminternational.com/contact-biopharm-international-editors>

CONTACT SALES < http://www.biopharminternational.com/contact-biopharm-international-sales>

SUBSCRIBE <<http://eforms.kmpsgroup.com/jointforms/Forms/Subscription.aspx?pubcode=BIOP&step=form&source=BIOPEBFT> >

ADVERTISE < http://www.biopharminternational.com/biopharm-international-advertising-opportunities-2015>